|Bid||6.36 x 0|
|Ask||6.50 x 0|
|Day's Range||6.47 - 6.90|
|52 Week Range||6.47 - 18.09|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abacus Health Products, Inc. will release its 2019 second quarter financial results sooner than previously announced. The Company will release the results on Tuesday, August 27, 2019, prior to market open.
Abacus Health Products, Inc. (ABCS.CN) (ABAHF) (“Abacus” or the “Company”) today announced the addition of Matrix Distributors, Inc. (“Matrix Distributors”) as a distributor of its CBDMEDIC™ products. The Company has also announced the expansion of retail stores carrying its products with both new and existing retail partners. Matrix Distributors, Inc., which serves over 1,000 independent pharmacies will initially roll out 9 CBDMEDIC™ products, including 6 unique pain relief SKUs, Acne Treatment Cream and Cleanser, and Eczema Treatment, to up to 250 locations across New York, New Jersey and Pennsylvania during 2019, with further roll-outs planned for 2020.
Abacus Health Products, Inc. will release its 2019 second quarter financial results on Thursday, August 29, 2019, after market close.
WOONSOCKET, RI and TORONTO , July 31, 2019 /CNW/ - Abacus Health Products, Inc. ("Abacus" or the "Company") (CSE: ABCS) (ABAHF) is pleased to announce that Mr. Hannan Fleiman has joined its board of directors. Mr. Fleiman will also serve as Chair of the Company's Audit Committee and Corporate Governance, Nominating and Compensation Committee. With the addition of Mr. Fleiman, Abacus now has a total of five directors on its board. "I am pleased to welcome Hannan Fleiman to Abacus' board of directors," said Perry Antelman , CEO of Abacus.
WOONSOCKET, RI , July 2, 2019 /CNW/ - Abacus Health Products, Inc. ("Abacus" or the "Company") (CSE: ABCS) (ABAHF) today announced its subordinate voting shares have begun trading on the OTCQX Market under the symbol "ABAHF" effective July 1, 2019 . "Having a dual listing on both the OTCQX and the CSE has been an important objective for our company," said Perry Antelman , CEO. This news release contains forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities legislation.
NEW YORK , July 1, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Abacus Health Products Inc (CSE: ABCS; ...
Abacus CEO Perry Antelman to Speak at the Inaugural Institutional Capital & Cannabis Conference Europe
TORONTO , May 30, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") reported its financial results today for the first quarter ended March 31, 2019 . CBD CLINIC continued to perform well with revenue increasing 148% YoY, from $1,433,243 to $3,553,751 , and an increase of 23% over the fourth quarter of 2018, from $2,886,412 . Purchase orders received to date represent over 2,000 retail pharmacy and supermarket locations across 11 states.
WOONSOCKET, RI and TORONTO, May 23, 2019 /PRNewswire/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced that renowned Hollywood fitness trainer and nutritional expert, Harley Pasternak, will be working with the Company to increase public awareness of its CBDMEDIC™ line of pain relief and skincare products. Pasternak holds a Master of Science in Exercise Physiology and Nutritional Sciences from the University of Toronto and an Honors Degree in Kinesiology from the University of Western Ontario.
Abacus Health Products Announces Release Date, Conference Call and Webcast Details for 2019 First Quarter Financial Results
WOONSOCKET, RI and TORONTO, May 10, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced further growth in the distribution and availability of their line of CBDMEDIC™ products. "These purchase orders, which range from six to twelve unique SKUs across our pain relief and therapeutic skincare lines, demonstrate the continued strong interest by retail chains to bring CBDMEDIC™ products onto their shelves," said Perry Antelman , CEO of Abacus. Further, a 2018 research report by Allied Market Research estimated the global topical pain relief market to be approximately US$7.4 billion in 2017.
WOONSOCKET, RI , April 17, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced the hiring of two new members to its senior management team. James Barkat has been named Vice President of Marketing for Abacus. Prior to joining the Company, Mr. Barkat spent over ten years at Sanofi Consumer Health, where he most recently served as U.S. Marketing Head – Digestive Health, a $300 million portfolio that includes brands such as Dulcolax, Zantac, and Rolaids.
Each Unit will be comprised of one subordinate voting share of the Company (a “Subordinate Voting Share”) and one-half of one Subordinate Voting Share purchase warrant (each whole warrant, a “Warrant”).
The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $2,250,150 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $17,251,150.
WOONSOCKET, RI , April 11, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced the latest round of purchase orders for their line of CBDMEDIC™ products. "These new purchase orders demonstrate strong momentum and the successful execution of our retail growth strategy," said Perry Antelman , CEO of Abacus.